US2913451A
(en)
*
|
1957-04-04 |
1959-11-17 |
Mallinckrodt Chemical Works |
Iodophenylamidoalkanesulfonic acid compounds
|
US5700444A
(en)
*
|
1992-02-20 |
1997-12-23 |
Rhomed Incorporated |
Chemotactic peptide pharmaceutical applications
|
US5759515A
(en)
*
|
1989-08-09 |
1998-06-02 |
Rhomed Incorporated |
Polyvalent peptide pharmaceutical applications
|
US6146657A
(en)
*
|
1989-12-22 |
2000-11-14 |
Imarx Pharmaceutical Corp. |
Gas-filled lipid spheres for use in diagnostic and therapeutic applications
|
US5773024A
(en)
*
|
1989-12-22 |
1998-06-30 |
Imarx Pharmaceutical Corp. |
Container with multi-phase composition for use in diagnostic and therapeutic applications
|
US5469854A
(en)
|
1989-12-22 |
1995-11-28 |
Imarx Pharmaceutical Corp. |
Methods of preparing gas-filled liposomes
|
US5305757A
(en)
*
|
1989-12-22 |
1994-04-26 |
Unger Evan C |
Gas filled liposomes and their use as ultrasonic contrast agents
|
US5585112A
(en)
*
|
1989-12-22 |
1996-12-17 |
Imarx Pharmaceutical Corp. |
Method of preparing gas and gaseous precursor-filled microspheres
|
OA10149A
(en)
*
|
1991-03-29 |
1996-12-18 |
Genentech Inc |
Vascular endothelial cell growth factor antagonists
|
US20020032313A1
(en)
|
1991-03-29 |
2002-03-14 |
Genentech, Inc. |
Vascular endothelial cell growth factor antagonists
|
US5205290A
(en)
*
|
1991-04-05 |
1993-04-27 |
Unger Evan C |
Low density microspheres and their use as contrast agents for computed tomography
|
US5861301A
(en)
*
|
1992-02-20 |
1999-01-19 |
American Cayanamid Company |
Recombinant kinase insert domain containing receptor and gene encoding same
|
ATE239506T1
(de)
|
1992-03-05 |
2003-05-15 |
Univ Texas |
Verwendung von immunokonjugate zur diagnose und/oder therapie der vaskularisierten tumoren
|
US5965132A
(en)
*
|
1992-03-05 |
1999-10-12 |
Board Of Regents, The University Of Texas System |
Methods and compositions for targeting the vasculature of solid tumors
|
WO1993022343A1
(en)
*
|
1992-05-01 |
1993-11-11 |
The Rockfeller University |
Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom
|
US6824777B1
(en)
*
|
1992-10-09 |
2004-11-30 |
Licentia Ltd. |
Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
|
ATE348110T1
(de)
|
1992-10-28 |
2007-01-15 |
Genentech Inc |
Hvegf rezeptor als vegf antagonist
|
DE69434538T2
(de)
*
|
1994-03-08 |
2006-08-10 |
Human Genome Sciences, Inc. |
Vaskulärer endothelialer Wachstumsfaktor 2
|
US6645933B1
(en)
|
1995-08-01 |
2003-11-11 |
Helsinki University Licensing Ltd. Oy |
Receptor ligand VEGF-C
|
US6221839B1
(en)
*
|
1994-11-14 |
2001-04-24 |
Helsinki University Licensing Ltd. Oy |
FIt4 ligand and methods of use
|
US6245530B1
(en)
*
|
1995-08-01 |
2001-06-12 |
Ludwig Institute For Cancer Research |
Receptor ligand
|
US6403088B1
(en)
*
|
1995-08-01 |
2002-06-11 |
Helsinki University Licensing, Ltd. |
Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
|
US6130071A
(en)
*
|
1997-02-05 |
2000-10-10 |
Helsinki University Licensing, Ltd. |
Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
|
ATE265863T1
(de)
|
1995-06-07 |
2004-05-15 |
Imarx Pharmaceutical Corp |
Neue zielgerichtete mittel zur diagnostischen und therapeutischen verwendung
|
US6521211B1
(en)
*
|
1995-06-07 |
2003-02-18 |
Bristol-Myers Squibb Medical Imaging, Inc. |
Methods of imaging and treatment with targeted compositions
|
US6033645A
(en)
*
|
1996-06-19 |
2000-03-07 |
Unger; Evan C. |
Methods for diagnostic imaging by regulating the administration rate of a contrast agent
|
US6231834B1
(en)
*
|
1995-06-07 |
2001-05-15 |
Imarx Pharmaceutical Corp. |
Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
|
US6361946B1
(en)
*
|
1997-02-05 |
2002-03-26 |
Licentia Ltd |
Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
|
US7423125B2
(en)
*
|
1995-08-01 |
2008-09-09 |
Vegenics Limited |
Antibodies to VEGF-C
|
EP0848755B2
(en)
*
|
1995-09-08 |
2011-02-09 |
Genentech, Inc. |
Vegf-related protein
|
US6261537B1
(en)
*
|
1996-10-28 |
2001-07-17 |
Nycomed Imaging As |
Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
|
US6264917B1
(en)
*
|
1996-10-28 |
2001-07-24 |
Nycomed Imaging As |
Targeted ultrasound contrast agents
|
GB9708265D0
(en)
|
1997-04-24 |
1997-06-18 |
Nycomed Imaging As |
Contrast agents
|
NZ335799A
(en)
|
1996-10-28 |
2000-11-24 |
Nycomed Imaging As |
Improvements in or relating to diagnostic/therapeutic agents
|
US6331289B1
(en)
*
|
1996-10-28 |
2001-12-18 |
Nycomed Imaging As |
Targeted diagnostic/therapeutic agents having more than one different vectors
|
US7125714B2
(en)
*
|
1997-02-05 |
2006-10-24 |
Licentia Ltd. |
Progenitor cell materials and methods
|
US20020010137A1
(en)
*
|
1997-09-18 |
2002-01-24 |
Genentech, Inc. |
Methods and compositions for inhibiting neoplastic cell growth
|
US6245318B1
(en)
*
|
1997-05-27 |
2001-06-12 |
Mallinckrodt Inc. |
Selectively binding ultrasound contrast agents
|
WO1998058053A1
(en)
*
|
1997-06-18 |
1998-12-23 |
Merck & Co., Inc. |
Human receptor tyrosine kinase, kdr
|
US6777534B1
(en)
*
|
1997-12-09 |
2004-08-17 |
Children's Medical Center Corporation |
Peptide antagonists of vascular endothelial growth factor
|
CA2321026A1
(en)
*
|
1998-03-09 |
1999-09-16 |
Zealand Pharmaceuticals A/S |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
US6548663B1
(en)
*
|
1998-03-31 |
2003-04-15 |
Bristol-Myers Squibb Pharma Company |
Benzodiazepine vitronectin receptor antagonist pharmaceuticals
|
US6537520B1
(en)
*
|
1998-03-31 |
2003-03-25 |
Bristol-Myers Squibb Pharma Company |
Pharmaceuticals for the imaging of angiogenic disorders
|
US6524553B2
(en)
*
|
1998-03-31 |
2003-02-25 |
Bristol-Myers Squibb Pharma Company |
Quinolone vitronectin receptor antagonist pharmaceuticals
|
EA200001007A1
(ru)
|
1998-03-31 |
2001-04-23 |
Дюпон Фармасьютикалз Компани |
Фармацевтические препараты для визуализации ангиогенных расстройств
|
US6548048B1
(en)
*
|
1998-04-28 |
2003-04-15 |
Amersham Health As |
Lipopeptide stabilized microbubbles as diagnostic/therapeutic agents
|
US6875741B2
(en)
*
|
1998-09-02 |
2005-04-05 |
Renuka Pillutla |
Insulin and IGF-1 receptor agonists and antagonists
|
US7173005B2
(en)
*
|
1998-09-02 |
2007-02-06 |
Antyra Inc. |
Insulin and IGF-1 receptor agonists and antagonists
|
US20030236190A1
(en)
*
|
1998-09-02 |
2003-12-25 |
Renuka Pillutla |
Isulin and IGF-1 receptor agonists and antagonists
|
DE19941092A1
(de)
|
1999-08-30 |
2001-03-01 |
Philips Corp Intellectual Pty |
Netzwerk mit einer Kennungsreduktion
|
US7045133B2
(en)
*
|
2000-01-18 |
2006-05-16 |
Ludwig Institute For Cancer Research |
VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor
|
US7740841B1
(en)
*
|
2000-01-28 |
2010-06-22 |
Sunnybrook Health Science Center |
Therapeutic method for reducing angiogenesis
|
WO2001057067A1
(en)
*
|
2000-02-04 |
2001-08-09 |
Supratek Pharma Inc. |
Ligand for vascular endothelial growth factor receptor
|
US20020102260A1
(en)
*
|
2000-03-02 |
2002-08-01 |
Marc Achen |
Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
|
ATE533056T1
(de)
|
2000-03-02 |
2011-11-15 |
Vegenics Pty Ltd |
Verfahren zum auffinden von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren
|
EP1519193B1
(en)
|
2000-03-02 |
2011-11-09 |
Vegenics Pty Ltd |
Methods for detecting cancers expressing vascular endothelial growth factor D
|
US20010031485A1
(en)
*
|
2000-03-22 |
2001-10-18 |
Sibtech, Inc. |
Recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor fragments
|
EP1268544A2
(en)
*
|
2000-03-31 |
2003-01-02 |
Institut Pasteur |
Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof
|
US6689352B2
(en)
*
|
2000-05-03 |
2004-02-10 |
Ludwig Institute For Cancer Research |
Method for activating only the vascular endothelial growth factor receptor-3 and uses thereof
|
EP1166798A1
(en)
|
2000-06-23 |
2002-01-02 |
Schering Aktiengesellschaft |
Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/ Tie receptor function and their use
|
KR20080068151A
(ko)
*
|
2000-06-23 |
2008-07-22 |
바이엘 쉐링 파마 악티엔게젤샤프트 |
VEGF/VEGF 수용체 및 안지오포이에틴/Tie수용체의 기능을 방해하는 조합 제제 및 조성물과 이들의용도 (Ⅱ)
|
EP1166799A1
(en)
|
2000-06-28 |
2002-01-02 |
Schering Aktiengesellschaft |
Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/Tie receptor function and their use (II)
|
US7175844B2
(en)
*
|
2000-07-18 |
2007-02-13 |
Joslin Diabetes Center, Inc. |
Methods of modulating fibrosis
|
US20020091082A1
(en)
*
|
2000-09-13 |
2002-07-11 |
Aiello Lloyd P. |
Methods of modulating symptoms of hypertension
|
US20030082103A1
(en)
*
|
2000-10-11 |
2003-05-01 |
Targesome, Inc. |
Targeted therapeutic lipid constructs having cell surface targets
|
US20020091567A1
(en)
*
|
2001-01-09 |
2002-07-11 |
Royston Tymarshall E. |
System and method for electronically redeeming coupons
|
US7611711B2
(en)
*
|
2001-01-17 |
2009-11-03 |
Vegenics Limited |
VEGFR-3 inhibitor materials and methods
|
CA2439953A1
(en)
*
|
2001-03-08 |
2002-09-19 |
Mark D. Bednarski |
Stabilized therapeutic and imaging agents
|
CA2444624A1
(en)
*
|
2001-04-13 |
2002-10-24 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
WO2003035839A2
(en)
*
|
2001-10-24 |
2003-05-01 |
Dgi Biotechnologies, Inc. |
Target specific screening andits use for identifying target binders
|
US7211240B2
(en)
|
2002-03-01 |
2007-05-01 |
Bracco International B.V. |
Multivalent constructs for therapeutic and diagnostic applications
|
US20050100963A1
(en)
|
2002-03-01 |
2005-05-12 |
Dyax Corporation |
KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
|
WO2003084574A1
(en)
*
|
2002-03-01 |
2003-10-16 |
Bracco International Bv |
Multivalent constructs for therapeutic and diagnostic applications
|
ES2398393T3
(es)
*
|
2002-03-01 |
2013-03-15 |
Dyax Corp. |
Péptidos de unión a KDR y a VEGF/KDR y su uso en diagnóstico y terapia
|
JP2005524710A
(ja)
*
|
2002-05-06 |
2005-08-18 |
ジェネンテック・インコーポレーテッド |
骨欠陥の治療へのvegfの用途
|
US20040212193A1
(en)
|
2002-10-08 |
2004-10-28 |
Johnstone Ian David |
Connector
|
NO20026285D0
(no)
|
2002-12-30 |
2002-12-30 |
Amersham Health As |
Nye peptider
|
NO20026286D0
(no)
*
|
2002-12-30 |
2002-12-30 |
Amersham Health As |
Nye peptider
|
US7183256B2
(en)
*
|
2003-03-21 |
2007-02-27 |
Cleveland Clinic Foundation |
TIMP3 as VEGF inhibitor
|
US7601341B2
(en)
*
|
2003-06-05 |
2009-10-13 |
Research Development Foundation |
Vascular endothelial growth factor fusion constructs used to inhibit osteoclastogenesis
|
WO2005016963A2
(en)
|
2003-06-12 |
2005-02-24 |
Ludwig Institute For Cancer Research |
Heparin binding veger-3 ligands
|
EP1635860A2
(en)
|
2003-06-12 |
2006-03-22 |
Ludwig Institute For Cancer Research |
Use of vegf-c or vegf-d in reconstructive surgery
|
JP2005110508A
(ja)
|
2003-10-02 |
2005-04-28 |
Nec Soft Ltd |
血管内皮増殖因子受容体2型に対する特異的結合性を有するヘビ毒由来血管内皮増殖因子様タンパク質と用途
|
WO2005070472A2
(en)
|
2004-01-20 |
2005-08-04 |
Sunnybrook And Women's College Health Sciences Centre, |
High frequency ultrasound imaging using contrast agents
|
US8067368B2
(en)
|
2004-01-27 |
2011-11-29 |
The Ohio State University Research Foundation |
Vascular endothelial growth factors and methods of their use
|
CA2575622A1
(en)
|
2004-08-06 |
2006-02-09 |
Sopherion Therapeutics, Inc. |
Anti-angiogenic peptides and methods of use thereof
|